US5824668A - Formulation for administration of steroid compounds - Google Patents
Formulation for administration of steroid compounds Download PDFInfo
- Publication number
- US5824668A US5824668A US08/744,979 US74497996A US5824668A US 5824668 A US5824668 A US 5824668A US 74497996 A US74497996 A US 74497996A US 5824668 A US5824668 A US 5824668A
- Authority
- US
- United States
- Prior art keywords
- composition
- etiocholanolone
- cyclodextrin
- steroid
- etiocholandione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (43)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/744,979 US5824668A (en) | 1996-11-07 | 1996-11-07 | Formulation for administration of steroid compounds |
AU11587/97A AU718232B2 (en) | 1995-11-13 | 1996-11-12 | Improved formulation for administration of steroid compounds |
EP96942747A EP0866722A1 (en) | 1995-11-13 | 1996-11-12 | Improved formulation for administration of steroid compounds |
PCT/US1996/018189 WO1997017992A1 (en) | 1995-11-13 | 1996-11-12 | Improved formulation for administration of steroid compounds |
IL12400196A IL124001A (en) | 1995-11-13 | 1996-11-12 | Composition for administration of steroids |
CA002237023A CA2237023C (en) | 1995-11-13 | 1996-11-12 | Improved formulation for administration of steroid compounds |
JP51903597A JP2002507960A (en) | 1995-11-13 | 1996-11-12 | Improved formulation for steroid compound administration |
CN96198150A CN1201397A (en) | 1995-11-13 | 1996-11-12 | Improved prescription for steroid compound administration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/744,979 US5824668A (en) | 1996-11-07 | 1996-11-07 | Formulation for administration of steroid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US5824668A true US5824668A (en) | 1998-10-20 |
Family
ID=24994717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/744,979 Expired - Fee Related US5824668A (en) | 1995-11-13 | 1996-11-07 | Formulation for administration of steroid compounds |
Country Status (1)
Country | Link |
---|---|
US (1) | US5824668A (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376657B1 (en) | 1997-04-15 | 2002-04-23 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US20020065256A1 (en) * | 1997-11-14 | 2002-05-30 | Ann-Kristin Karlsson | New composition of matter |
US20020068720A1 (en) * | 2000-08-22 | 2002-06-06 | Sims Sandra M. | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
US20020146468A1 (en) * | 2000-06-30 | 2002-10-10 | Rubin Ian Duncan | Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US20040019012A1 (en) * | 2002-02-22 | 2004-01-29 | Singh Satish K. | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
US20040043973A1 (en) * | 2000-03-16 | 2004-03-04 | Ahlem Clarence N. | Pharmaceutical compositions and treatment methods |
US20040072797A1 (en) * | 2002-03-20 | 2004-04-15 | Pornanong Aramwit | Storage stable eplerenone formulation |
US20040176321A1 (en) * | 2002-12-31 | 2004-09-09 | Wockhardt Limited | Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
WO2005011617A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
US20050079233A1 (en) * | 1999-10-27 | 2005-04-14 | John Hakkinen | Gastric acid secretion |
US20050260252A1 (en) * | 2002-10-31 | 2005-11-24 | Galit Levin | Transdermal delivery system for anti-emetic medication |
US20050287217A1 (en) * | 2002-10-31 | 2005-12-29 | Galit Levin | Transdermal delivery system for water insoluble drugs |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20080075784A1 (en) * | 2004-07-22 | 2008-03-27 | Pfizer Inc. | Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form |
EP1955700A2 (en) | 1999-09-30 | 2008-08-13 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
US20090215735A1 (en) * | 2002-02-25 | 2009-08-27 | Alcon, Inc. | Topical solution formulations containing a corticosteroid and a cyclodextrin |
US20100197646A1 (en) * | 2002-02-19 | 2010-08-05 | Resolution Chemicals Limited | Solvent-based sterilisation of pharmaceuticals |
US20110009372A1 (en) * | 1998-11-24 | 2011-01-13 | Frincke James M | Compounds and compositions |
US8114438B2 (en) | 2004-04-23 | 2012-02-14 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US20140212457A1 (en) * | 2005-09-06 | 2014-07-31 | Abdalla Rifai | Compounds |
US8829182B2 (en) | 2005-10-26 | 2014-09-09 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
KR101468153B1 (en) * | 2010-09-21 | 2014-12-01 | 광저우 셀프로텍 파머수티컬 리미티드 | 5α-ANDROSTANE-3β,5,6β-TRIOL INJECTION AND PREPARATION METHOD THEREFOR |
US20190105404A1 (en) * | 2003-12-31 | 2019-04-11 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2020163026A1 (en) | 2019-02-05 | 2020-08-13 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024223A (en) * | 1972-11-11 | 1977-05-17 | Teijin Limited | Stripe composition and method of reducing smell associated therewith |
US4228160A (en) * | 1978-01-27 | 1980-10-14 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Inclusion complex of cyclodextrin and indomethacin and a process for the preparation thereof, method of use and pharmaceutical composition |
US4232009A (en) * | 1978-03-01 | 1980-11-04 | Ono Pharmaceutical Co. Ltd. | ω-Halo-PGI2 analogues |
US4351846A (en) * | 1980-05-12 | 1982-09-28 | Ono Pharmaceutical Co., Ltd. | 3-Hydroxy and 3-oxo-prostaglandin analogues |
US4352793A (en) * | 1979-04-26 | 1982-10-05 | Sumitomo Chemical Company, Limited | Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
US4438106A (en) * | 1981-07-16 | 1984-03-20 | Kureha Kagaku Kabushiki Kaisha | Inclusion compound of eicosapentaenoic acid or docosahexaenoic acid with cyclodextrin |
US4474811A (en) * | 1981-12-24 | 1984-10-02 | Kakenyaku Kako Co., Ltd. | Anti-inflammatory ophthalmic solution and process for preparing the same |
US4478995A (en) * | 1981-09-01 | 1984-10-23 | Teikoku Chemical Industry Co., Ltd. | Complex compounds |
US4479944A (en) * | 1977-05-06 | 1984-10-30 | Ono Pharmaceutical Co., Ltd. | Composition containing PGI2 analogs stabilized |
US4479966A (en) * | 1978-03-31 | 1984-10-30 | Ono Pharmaceutical Company, Ltd. | 6,9-Methano-PGI2 analogues |
US4497803A (en) * | 1982-04-12 | 1985-02-05 | Takeda Chemical Industries, Ltd. | Inclusion compound of lankacidin-group antibiotic and use thereof |
US4499085A (en) * | 1982-04-30 | 1985-02-12 | Ono Pharmaceutical Co., Ltd. | Method of anoxia treatment using prostaglandin analogues |
US4507289A (en) * | 1983-12-28 | 1985-03-26 | Progenics, Inc. | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen |
US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
US4524068A (en) * | 1982-11-09 | 1985-06-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Cyclodextrin inclusion complex of piperonyl butoxide |
EP0149220A2 (en) * | 1983-12-28 | 1985-07-24 | The Jackson Laboratory | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones |
US4555504A (en) * | 1981-01-23 | 1985-11-26 | Burroughs Wellcome Co. | Inclusion complex of β-cyclodextrin and digoxin |
US4565807A (en) * | 1982-07-19 | 1986-01-21 | Ciba-Geigy Corporation | Medicinal composition containing pirprofen and cyclodextrin and a method of use |
US4575548A (en) * | 1983-10-11 | 1986-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Occlusion compound of 2-nitroxymethyl-6-chloropyridine with β-cyclodextrin and process for preparation thereof |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4598070A (en) * | 1983-07-21 | 1986-07-01 | Eisai Co., Ltd. | Tripamide and cyclodextrin inclusion compound |
US4603123A (en) * | 1984-02-22 | 1986-07-29 | Chiesi Farmaceutici, S.P.A. | Compounds having antiinflammatory activity, obtained by complexation of piroxican with β-cyclodextrin, and pharmaceutical compositions containing them |
US4608366A (en) * | 1985-03-11 | 1986-08-26 | Taiyo Pharmaceutical Industry Co., Ltd. | Oral cyclodextrin and mobenzoxamine preparation |
US4623641A (en) * | 1985-09-09 | 1986-11-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4663316A (en) * | 1985-06-28 | 1987-05-05 | Warner-Lambert Company | Antibiotic clathrates and pharmaceutical compositions thereof |
US4675395A (en) * | 1984-03-14 | 1987-06-23 | Seiwa Technological Laboratories Limited | Cyclodextrin inclusion compound and process for its preparation |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4728510A (en) * | 1985-06-13 | 1988-03-01 | Japan Liquid Crystal Co., Ltd. | Bath preparations and method for producing the same |
US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
EP0261891A2 (en) * | 1986-09-22 | 1988-03-30 | Progenics, Inc. | Pharmaceutical compositions containing etiochiolandione |
US4751095A (en) * | 1983-07-28 | 1988-06-14 | Karl Curtis L | Aspartame stabilization with cyclodextrin |
US4871726A (en) * | 1987-07-28 | 1989-10-03 | Progenics, Inc. | Increasing the bioavailability of alpha-etiocholanolone |
US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
US5006517A (en) * | 1987-12-01 | 1991-04-09 | Progenics, Inc. | Treatment of Prader-Willi syndrome |
EP0477107A1 (en) * | 1990-09-21 | 1992-03-25 | Laboratoires BESINS ISCOVESCO Société anonyme dite : | Steroids contained in cyclodextrins |
WO1992004888A1 (en) * | 1990-09-20 | 1992-04-02 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers |
-
1996
- 1996-11-07 US US08/744,979 patent/US5824668A/en not_active Expired - Fee Related
Patent Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024223A (en) * | 1972-11-11 | 1977-05-17 | Teijin Limited | Stripe composition and method of reducing smell associated therewith |
US4479944A (en) * | 1977-05-06 | 1984-10-30 | Ono Pharmaceutical Co., Ltd. | Composition containing PGI2 analogs stabilized |
US4228160A (en) * | 1978-01-27 | 1980-10-14 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Inclusion complex of cyclodextrin and indomethacin and a process for the preparation thereof, method of use and pharmaceutical composition |
US4232009A (en) * | 1978-03-01 | 1980-11-04 | Ono Pharmaceutical Co. Ltd. | ω-Halo-PGI2 analogues |
US4479966A (en) * | 1978-03-31 | 1984-10-30 | Ono Pharmaceutical Company, Ltd. | 6,9-Methano-PGI2 analogues |
US4352793A (en) * | 1979-04-26 | 1982-10-05 | Sumitomo Chemical Company, Limited | Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin |
US4351846A (en) * | 1980-05-12 | 1982-09-28 | Ono Pharmaceutical Co., Ltd. | 3-Hydroxy and 3-oxo-prostaglandin analogues |
US4555504A (en) * | 1981-01-23 | 1985-11-26 | Burroughs Wellcome Co. | Inclusion complex of β-cyclodextrin and digoxin |
US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
US4438106A (en) * | 1981-07-16 | 1984-03-20 | Kureha Kagaku Kabushiki Kaisha | Inclusion compound of eicosapentaenoic acid or docosahexaenoic acid with cyclodextrin |
US4478995A (en) * | 1981-09-01 | 1984-10-23 | Teikoku Chemical Industry Co., Ltd. | Complex compounds |
US4474811A (en) * | 1981-12-24 | 1984-10-02 | Kakenyaku Kako Co., Ltd. | Anti-inflammatory ophthalmic solution and process for preparing the same |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4497803A (en) * | 1982-04-12 | 1985-02-05 | Takeda Chemical Industries, Ltd. | Inclusion compound of lankacidin-group antibiotic and use thereof |
US4499085A (en) * | 1982-04-30 | 1985-02-12 | Ono Pharmaceutical Co., Ltd. | Method of anoxia treatment using prostaglandin analogues |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
US4565807A (en) * | 1982-07-19 | 1986-01-21 | Ciba-Geigy Corporation | Medicinal composition containing pirprofen and cyclodextrin and a method of use |
US4524068A (en) * | 1982-11-09 | 1985-06-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Cyclodextrin inclusion complex of piperonyl butoxide |
US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
US4598070A (en) * | 1983-07-21 | 1986-07-01 | Eisai Co., Ltd. | Tripamide and cyclodextrin inclusion compound |
US4751095A (en) * | 1983-07-28 | 1988-06-14 | Karl Curtis L | Aspartame stabilization with cyclodextrin |
US4575548A (en) * | 1983-10-11 | 1986-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Occlusion compound of 2-nitroxymethyl-6-chloropyridine with β-cyclodextrin and process for preparation thereof |
US4507289A (en) * | 1983-12-28 | 1985-03-26 | Progenics, Inc. | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen |
EP0149220A2 (en) * | 1983-12-28 | 1985-07-24 | The Jackson Laboratory | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones |
US4666898A (en) * | 1983-12-28 | 1987-05-19 | Jackson Lab. | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones |
US4603123A (en) * | 1984-02-22 | 1986-07-29 | Chiesi Farmaceutici, S.P.A. | Compounds having antiinflammatory activity, obtained by complexation of piroxican with β-cyclodextrin, and pharmaceutical compositions containing them |
US4675395A (en) * | 1984-03-14 | 1987-06-23 | Seiwa Technological Laboratories Limited | Cyclodextrin inclusion compound and process for its preparation |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4608366A (en) * | 1985-03-11 | 1986-08-26 | Taiyo Pharmaceutical Industry Co., Ltd. | Oral cyclodextrin and mobenzoxamine preparation |
US4728510A (en) * | 1985-06-13 | 1988-03-01 | Japan Liquid Crystal Co., Ltd. | Bath preparations and method for producing the same |
US4663316A (en) * | 1985-06-28 | 1987-05-05 | Warner-Lambert Company | Antibiotic clathrates and pharmaceutical compositions thereof |
US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
US4623641A (en) * | 1985-09-09 | 1986-11-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes |
EP0261891A2 (en) * | 1986-09-22 | 1988-03-30 | Progenics, Inc. | Pharmaceutical compositions containing etiochiolandione |
US4871726A (en) * | 1987-07-28 | 1989-10-03 | Progenics, Inc. | Increasing the bioavailability of alpha-etiocholanolone |
US5006517A (en) * | 1987-12-01 | 1991-04-09 | Progenics, Inc. | Treatment of Prader-Willi syndrome |
US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
US5024998A (en) * | 1987-12-30 | 1991-06-18 | University Of Florida | Pharmaceutical formulations for parenteral use |
US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
WO1992004888A1 (en) * | 1990-09-20 | 1992-04-02 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers |
EP0477107A1 (en) * | 1990-09-21 | 1992-03-25 | Laboratoires BESINS ISCOVESCO Société anonyme dite : | Steroids contained in cyclodextrins |
Non-Patent Citations (24)
Title |
---|
Bekers et al., "Stabilization of Mitomycins on Complexation With Cyclodextrins in Aqueous Acidic Media", Intl. J. of Pharmaceutics, 52, 239 (1989). |
Bekers et al., Stabilization of Mitomycins on Complexation With Cyclodextrins in Aqueous Acidic Media , Intl. J. of Pharmaceutics , 52, 239 (1989). * |
Bradlow et al., "Some Aspects of the Dynamics of Oxidation-Reduction of Etiocholanolone-3-3 H-14 C in Man", J. Clin. Endocr., 27, 1203 (1967). |
Bradlow et al., Some Aspects of the Dynamics of Oxidation Reduction of Etiocholanolone 3 3 H 14 C in Man , J. Clin. Endocr. , 27, 1203 (1967). * |
Brewster, M. et al. "Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-β-cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse", J. Pharm. Sciences, 84:10, 1154-1159 (Oct. 1995). |
Brewster, M. et al. Preparation, Characterization, and Anesthetic Properties of 2 Hydroxypropyl cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse , J. Pharm. Sciences , 84:10, 1154 1159 (Oct. 1995). * |
Coleman et al., "Therapeutic Effects of Dehydroepiandrosterone Metabolites in Diabetes Mutant Mice", Endocrinology, 115, 239 (184). |
Coleman et al., Therapeutic Effects of Dehydroepiandrosterone Metabolites in Diabetes Mutant Mice , Endocrinology , 115, 239 (184). * |
Coleman, "Diabetes-Obesity Syndromes in Mice", Diabetes, 31 (Suppl. 1), 1 (1982). |
Coleman, Antiobesity Effects of Etiocholanolones in Diabetes (db), Viable Yellow (A vy ), and Normal Mice Endocrinology , 117, 2279 (1985). * |
Coleman, Antiobesity Effects of Etiocholanolones in Diabetes (db), Viable Yellow (Avy), and Normal Mice Endocrinology, 117, 2279 (1985). |
Coleman, Diabetes Obesity Syndromes in Mice , Diabetes , 31 (Suppl. 1), 1 (1982). * |
Gardner et al., "Androstane Therapy to Treat Aplastic Anaemia in Adults: An Uncontrolled Pilot Study", British Journal of Hematology, 65, 295 (1987). |
Gardner et al., Androstane Therapy to Treat Aplastic Anaemia in Adults: An Uncontrolled Pilot Study , British Journal of Hematology , 65, 295 (1987). * |
Kappas et al., "Studies on Pyrogenic Steroids in Man", Tans. Assn. Am. Phys., 72, 54 (1959). |
Kappas et al., "The Pyrogenic Effect of Etiocholanolone (3α-Hydroxyetiocholane-17-One)", J. Clin. Endocr., 16, 948 (1956). |
Kappas et al., Studies on Pyrogenic Steroids in Man , Tans. Assn. Am. Phys. , 72, 54 (1959). * |
Kappas et al., The Pyrogenic Effect of Etiocholanolone (3 Hydroxyetiocholane 17 One) , J. Clin. Endocr. , 16, 948 (1956). * |
Shimada, et al., "Studies on Neurosteriods.I.Retention Behavior of Derivatized 17-Oxosteroids Using High-Performance Liquid Chromatography", J. Liquid Chromatography, 18:4, 712-723 (1995). |
Shimada, et al., Studies on Neurosteriods.I.Retention Behavior of Derivatized 17 Oxosteroids Using High Performance Liquid Chromatography , J. Liquid Chromatography , 18:4, 712 723 (1995). * |
Yen et al., "Prevention of Obesity in Avy /a Mice by Dehydroepiandrosterone", Lipids, 12(5), 409 (1977). |
Yen et al., Prevention of Obesity in A vy /a Mice by Dehydroepiandrosterone , Lipids , 12(5), 409 (1977). * |
Zumoff et al., "A Randomized Double-Blind Crossover Study of the Antiobesity Effects of Etiocholanedione", Obesity Research, 2, 13 (1994). |
Zumoff et al., A Randomized Double Blind Crossover Study of the Antiobesity Effects of Etiocholanedione , Obesity Research , 2, 13 (1994). * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7166611B2 (en) | 1997-04-15 | 2007-01-23 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US6376657B1 (en) | 1997-04-15 | 2002-04-23 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US20040228935A1 (en) * | 1997-04-15 | 2004-11-18 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US20030086984A1 (en) * | 1997-04-15 | 2003-05-08 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US7524834B2 (en) * | 1997-11-14 | 2009-04-28 | Astrazeneca Ab | Sterile powders, formulations, and methods for producing the same |
US20070197489A1 (en) * | 1997-11-14 | 2007-08-23 | Astrazeneca Ab A Swedish Corporation | Composition of matter |
US20020065256A1 (en) * | 1997-11-14 | 2002-05-30 | Ann-Kristin Karlsson | New composition of matter |
US20110009372A1 (en) * | 1998-11-24 | 2011-01-13 | Frincke James M | Compounds and compositions |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US8022234B2 (en) | 1998-11-24 | 2011-09-20 | Harbor Biosciences, Inc. | Compounds and compositions |
US8106036B2 (en) | 1999-03-23 | 2012-01-31 | Harbor Biosciences, Inc. | Pharmaceutical compositions-4 |
US20040220114A1 (en) * | 1999-03-23 | 2004-11-04 | Ahlem Clarence Nathaniel | Pharmaceutical compositions and treatment methods |
EP1955700A2 (en) | 1999-09-30 | 2008-08-13 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
US20110098260A1 (en) * | 1999-09-30 | 2011-04-28 | Harbor Biosciences, Inc. | Steroid Compounds and Formulations |
US8076316B2 (en) | 1999-09-30 | 2011-12-13 | Harbor Biosciences, Inc. | Steroid compounds and formulations |
US20050079233A1 (en) * | 1999-10-27 | 2005-04-14 | John Hakkinen | Gastric acid secretion |
US7501135B2 (en) | 1999-10-27 | 2009-03-10 | Conopco, Inc. | Gastric acid secretion |
US20040043973A1 (en) * | 2000-03-16 | 2004-03-04 | Ahlem Clarence N. | Pharmaceutical compositions and treatment methods |
US7396827B2 (en) | 2000-03-16 | 2008-07-08 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
US7033616B2 (en) | 2000-06-30 | 2006-04-25 | Phytopharm Plc | Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use |
US20060159779A1 (en) * | 2000-06-30 | 2006-07-20 | Phytopharm Plc | Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use |
US7416744B2 (en) | 2000-06-30 | 2008-08-26 | Conopco, Inc. | Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use |
US20020146468A1 (en) * | 2000-06-30 | 2002-10-10 | Rubin Ian Duncan | Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use |
US20020068720A1 (en) * | 2000-08-22 | 2002-06-06 | Sims Sandra M. | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
US20100197646A1 (en) * | 2002-02-19 | 2010-08-05 | Resolution Chemicals Limited | Solvent-based sterilisation of pharmaceuticals |
US20040019012A1 (en) * | 2002-02-22 | 2004-01-29 | Singh Satish K. | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
US20090215735A1 (en) * | 2002-02-25 | 2009-08-27 | Alcon, Inc. | Topical solution formulations containing a corticosteroid and a cyclodextrin |
US20040072797A1 (en) * | 2002-03-20 | 2004-04-15 | Pornanong Aramwit | Storage stable eplerenone formulation |
US20050260252A1 (en) * | 2002-10-31 | 2005-11-24 | Galit Levin | Transdermal delivery system for anti-emetic medication |
US7395111B2 (en) | 2002-10-31 | 2008-07-01 | Transpharma Medical Ltd. | Transdermal delivery system for water insoluble drugs |
US7415306B2 (en) | 2002-10-31 | 2008-08-19 | Transpharma Medical Ltd. | Transdermal delivery system for anti-emetic medication |
US20050287217A1 (en) * | 2002-10-31 | 2005-12-29 | Galit Levin | Transdermal delivery system for water insoluble drugs |
US20040176321A1 (en) * | 2002-12-31 | 2004-09-09 | Wockhardt Limited | Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
WO2005011617A3 (en) * | 2003-07-31 | 2007-05-24 | Ivax Corp | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
WO2005011617A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
US10799599B2 (en) * | 2003-12-31 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20190105404A1 (en) * | 2003-12-31 | 2019-04-11 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10668160B2 (en) | 2004-04-23 | 2020-06-02 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US10117940B2 (en) | 2004-04-23 | 2018-11-06 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US11464862B2 (en) | 2004-04-23 | 2022-10-11 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US8114438B2 (en) | 2004-04-23 | 2012-02-14 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US20080075784A1 (en) * | 2004-07-22 | 2008-03-27 | Pfizer Inc. | Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20140212457A1 (en) * | 2005-09-06 | 2014-07-31 | Abdalla Rifai | Compounds |
US9617352B2 (en) | 2005-10-26 | 2017-04-11 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US10202468B2 (en) | 2005-10-26 | 2019-02-12 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US8846901B2 (en) | 2005-10-26 | 2014-09-30 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US10703826B2 (en) | 2005-10-26 | 2020-07-07 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US8829182B2 (en) | 2005-10-26 | 2014-09-09 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
KR101468153B1 (en) * | 2010-09-21 | 2014-12-01 | 광저우 셀프로텍 파머수티컬 리미티드 | 5α-ANDROSTANE-3β,5,6β-TRIOL INJECTION AND PREPARATION METHOD THEREFOR |
WO2020163026A1 (en) | 2019-02-05 | 2020-08-13 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
US10836788B2 (en) | 2019-02-05 | 2020-11-17 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
US11667665B2 (en) | 2019-02-05 | 2023-06-06 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
US11685762B2 (en) | 2019-02-05 | 2023-06-27 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5824668A (en) | Formulation for administration of steroid compounds | |
Jansook et al. | Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications | |
US6583125B2 (en) | Formulation of nitrogen mustard | |
US4877774A (en) | Administration of steroid hormones | |
Conceicao et al. | Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art | |
Rajewski et al. | Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery | |
US4596795A (en) | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives | |
US5730969A (en) | Method and compositions for solubilization and stabilization of polypeptides, especially proteins | |
Merkus et al. | Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats | |
US5089482A (en) | Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin | |
KR100349754B1 (en) | Pharmaceutical composition | |
WO2004087121A2 (en) | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | |
Szejtli | Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: therefore the increase in number of marketed drug/cyclodextrin formulations is so slow | |
EA034565B1 (en) | Compositions of levosimendan for intravenous administration as infusion or injection and of infusion concentrate | |
Holbrook et al. | Aqueous hydrocortisone mouthwash solution: clinical evaluation | |
CA2237023C (en) | Improved formulation for administration of steroid compounds | |
Uekama et al. | Improvement of drug properties by cyclodextrins | |
US20050059615A1 (en) | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | |
EP0399716B1 (en) | Hypoallergenic steroidal anesthetic/hypnotic compositions | |
US20040014695A1 (en) | Pharmaceutical formulation | |
JP2005520856A (en) | Eplerenone formulation stable during storage | |
Brewster et al. | Intravenous and Buccal 2-Hydroxypropyl-β-Cyclodextrin Formulations of E2-CDS—Phase I Clinical Trials | |
Mishra et al. | CYCLODEXTRIN: A MULTIFUNCTIONAL DRUG CARRIER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STONY BROOK SURGICAL INNOVATIONS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCIAINO, BARTOLO, JR.;REEL/FRAME:008389/0478 Effective date: 19961007 |
|
AS | Assignment |
Owner name: SUPERGEN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUBINFELD, JOSEPH;VIDA, JULIUS A.;BRADLOW, H. LEON;AND OTHERS;REEL/FRAME:009102/0104 Effective date: 19961104 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20101020 |